Carl Zeiss Meditec: Why The Market Is Finally Recognizing The Recovery

Carl Zeiss Meditec has rebounded nearly 50% from its early-2026 lows after a downturn that included a 40% earnings decline and a 64% share-price drop. The analyst maintains a €65-per-share price target and a Buy rating, citing potential EBITA margin recovery to 15% and normalized EPS above €2.5 per share after 2027.

Analysis

The recovery case is an operating-leverage thesis, not yet a demonstrated earnings inflection: if volumes normalize while pricing and product mix hold, incremental sales could rebuild margins; if demand remains weak, a rebound in the shares can outpace any improvement in earnings. The article offers a post-2027 earnings scenario but no current valuation, order trends, regional demand data, or evidence that the margin path is underway. Treat the stated target as an analyst assumption, not independent confirmation.

For Carl Zeiss Meditec AG (AFX), the key competitive read-through is whether hospitals and clinicians resume spending on ophthalmic equipment. A sustained capex recovery could also benefit competitors such as Alcon and Topcon; it would not automatically establish AFX share gains. Conversely, constrained budgets could delay equipment replacement across the category and defer the operating leverage thesis.

Near term, the sharp rebound raises the risk that recovery expectations are already reflected in the price. Over 1–3 months, order intake, guidance, and reported EBITA margin progression matter more than the broad claim of resilience. Over 6–18 months, product adoption, regional mix, and the durability of demand will determine whether normalized earnings are credible. Falsifiers include continued margin deterioration, weak orders, or guidance that pushes recovery further out.

Key Decisions for Investors

• Do not chase AFX solely on the recovery narrative. Verify current valuation against a defensible earnings base and check the latest order intake, regional performance, and EBITA margin trend before adding exposure.
• For existing holders, retain exposure only while operating indicators stabilize; reduce if orders weaken or management delays margin recovery. The thesis is falsified by sustained deterioration, not simply by short-term share-price volatility.
• Watch Alcon and Topcon as category read-throughs, but do not treat sector-wide equipment demand as evidence of AFX-specific share gains. Compare order and guidance trends before expressing a relative-value view.
• No high-conviction new trade is warranted from this article alone: the recent repricing may have reduced near-term asymmetry, and the information needed to assess upside versus downside—especially valuation and current operating momentum—is missing.